PCN179 Real-World Evidence on Metastatic or Relapsing Head and Neck Cancer
Sign Up to like & getrecommendations! Published in 2020 at "Value in Health"
DOI: 10.1016/j.jval.2020.08.316
Abstract: CHALLENGES OF DESCRIPTIVE EPIDEMIOLOGY IN RARE DISEASES: A SYSTEMATIC LITERATURE REVIEW (SLR) AND META-ANALYSIS (MA) OF SOLID TUMORS WITH NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSIONS Anna F, Zhang WW, Strauss UP, Fellous M, Korei… read more here.
Keywords: epidemiology; histology; economics; pcn179 real ... See more keywords
Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China
Sign Up to like & getrecommendations! Published in 2022 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.14644
Abstract: Gene fusions can drive tumor development for multiple types of cancer. Currently, many drugs targeting gene fusions are being approved for clinical application. At present, tyrosine receptor kinase (TRK) inhibitors targeting neurotrophic tyrosine receptor kinase… read more here.
Keywords: fusion; ntrk gene; gene fusions; treatment ... See more keywords
Abstract 925: NTRK gene fusion in adults and pediatrics with solid tumors: a record linkage study of expression frequency and patient characteristics using the Auria Biobank in Finland
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-925
Abstract: Introduction: Selective tropomyosin receptor kinase (TRK) inhibitors are targeted therapies for patients with solid tumors harboring a neurotrophic-receptor tyrosine kinase (NTRK) gene fusion. Estimates of the frequency of NTRK gene fusions and knowledge about characteristics… read more here.
Keywords: ntrk gene; solid tumors; gene fusion; gene ... See more keywords
Abstract CT228: Concordance between tissue and circulating tumor DNA (ctDNA) testing for neurotrophic tyrosine receptor kinase (NTRK) gene fusions in larotrectinib (laro) clinical trials
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct228
Abstract: Background: NTRK gene fusions are oncogenic drivers in various tumor types. Laro, a highly selective and central nervous system (CNS)-active tropomyosin receptor kinase (TRK) inhibitor, is approved for the treatment of patients (pts) with TRK… read more here.
Keywords: fusion; ntrk gene; ctdna; gene fusions ... See more keywords
Abstract 09: Cancers with NTRK gene fusions: Molecular characteristics and prognosis
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1557-3265.advprecmed20-09
Abstract: Introduction: The neurotrophic tyrosine receptor kinase (NTRK) genes NTRK1, 2, and 3 have emerged as oncogenic drivers, and their resultant tropomyosin receptor kinase (TRK) proteins are targets for precision medicines. Larotrectinib, a selective TRK inhibitor,… read more here.
Keywords: gene fusions; fusion; pts trk; ntrk gene ... See more keywords
A novel agnostic tumor: NTRKoma
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/1078155221996049
Abstract: Precision medicine has revolutionized the cancer treatment and created the notion of tumor agnostic drug development. Agnostic tumor markers define a simple compound used against multiple tumor types. For instance, pembrolizumab for microsatellite instable tumors… read more here.
Keywords: medicine; tumor; tumor agnostic; ntrk gene ... See more keywords
NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Personalized Medicine"
DOI: 10.3390/jpm12111819
Abstract: The approval of larotrectinib and entrectinib for cancer patients harboring an NTRK gene fusion has represented a milestone in the era of “histology-agnostic” drugs. Among the clinical trials that led to the approval of these… read more here.
Keywords: ntrk gene; gene fusions; clinical trials; case ... See more keywords